Research

Built on peer-reviewed science

Our methods have been used in published studies on cancer, inflammation, infection and neurodegeneration, and we take part in European research projects and networks.

Selected publications

  1. Transl Neurodegener · 2026
    Brain region-resolved pharmacodynamics of an antisense oligonucleotide targeting human SNCA 3'UTR in BAC-hSNCA rats

    Naki M, Kattan FG, Pantazopoulou M, Skea S, Zisis D, Pilalis E, Fouka M, Koronaiou E, Fotis C, Riess O, Chatziioannou A, Alexopoulos LG, Stefanis L, Doxakis E

  2. EMBO Mol Med · 2026
    IRE1 activity is prognostic in localised and metastatic prostate cancer and affects epithelial lineage states

    Doultsinos D, Tomljanovic I, Pilalis E, Abusamra SM, Alshalalfa M, Parmentier R, Ahire V, Bridges IE, Figiel S, Hester J, Leach D, Nandakumar A, Wan R, Zekri Y, Zhang J, Bevan CL, O'Neill E, Lamb AD, Macauley V, Theurillat JP, Urbanucci A, Karnes RJ, Spratt DE, Davicioni E, Quigley D, Zwart W, Le Magnen C, Chatziioannou A, Mills IG

  3. Bioinformatics · 2025
    Pre-Meta: priors-augmented retrieval for LLM-based metadata generation

    Tinn P, Sørbø S, Jiang S, Voutetakis K, Giounis SM, Pilalis E, Papadodima O, Roman D

  4. Nature Communications · 2022
    Regulated IRE1α-dependent decay (RIDD)-mediated reprograming of lipid metabolism in cancer

    Almanza A, Mnich K, Blomme A, Robinson CM, Rodriguez-Blanco G, Kierszniowska S, McGrath EP, Le Gallo M, Pilalis E, Swinnen JV, Chatziioannou A, Chevet E, Gorman AM, Samali A

  5. J Cell Biol · 2020
    Role of the early secretory pathway in SARS-CoV-2 infection

    Sicari D, Chatziioannou A, Koutsandreas T, Sitia R, Chevet E

  6. Database · 2020
    RA-map: building a state-of-the-art interactive knowledge base for rheumatoid arthritis

    Singh V, Kalliolias GD, Ostaszewski M, Veyssiere M, Pilalis E, Gawron P, Mazein A, Bonnet E, Petit-Teixeira E, Niarakis A

  7. EMBO Mol Med · 2019
    Control of anterior GRadient 2 (AGR2) dimerization links endoplasmic reticulum proteostasis to inflammation

    Maurel M, Obacz J, Avril T, Ding YP, Papadodima O, Treton X, Daniel F, Pilalis E, Hörberg J, Hou W, Beauchamp MC, Tourneur-Marsille J, Cazals-Hatem D, Sommerova L, Samali A, Tavernier J, Hrstka R, Dupont A, Fessart D, Delom F, Fernandez-Zapico ME, Jansen G, Eriksson LA, Thomas DY, Jerome-Majewska L, Hupp T, Chatziioannou A, Chevet E, Ogier-Denis E

  8. Nature Communications · 2018

    Inhibition of IRE1 RNase activity modulates the tumor cell secretome and enhances response to chemotherapy

    Logue SE, McGrath EP, Cleary P, Greene S, Mnich K, Almanza A, Chevet E, Dwyer RM, Oommen A, Legembre P, Godey F, Madden EC, Leuzzi B, Obacz J, Zeng Q, Patterson JB, Jäger R, Gorman AM, Samali A

  9. Cell Metabolism · 2018
    Low-protein diet induces IRE1α-dependent anticancer immunosurveillance

    Rubio-Patiño C, Bossowski JP, De Donatis GM, Mondragón L, Villa E, Aira LE, Chiche J, Mhaidly R, Lebeaupin C, Marchetti S, Voutetakis K, Chatziioannou A, Castelli FA, Lamourette P, Chu-Van E, Fenaille F, Avril T, Passeron T, Patterson JB, Verhoeyen E, Bailly-Maitre B, Chevet E, Ricci JE

  10. EMBO Mol Med · 2018

    Dual IRE1 RNase functions dictate glioblastoma development

    Lhomond S, Avril T, Dejeans N, Voutetakis K, Doultsinos D, McMahon M, Pineau R, Obacz J, Papadodima O, Jouan F, Bourien H, Logotheti M, Jégou G, Pallares-Lupon N, Schmit K, Le Reste PJ, Etcheverry A, Mosser J, Barroso K, Vauléon E, Maurel M, Samali A, Patterson JB, Pluquet O, Hetz C, Quillien V, Chatziioannou A, Chevet E

Research networks and programmes

Horizon Europe · MSCA-SE · 101300062

DiagMDS

Non-invasive diagnosis of myelodysplastic syndromes

New ways to diagnose myelodysplastic syndromes from peripheral blood, studying the immune microenvironment, chromatin, methylation, extracellular vesicle cargo, mitochondrial DNA and metabolome. 2026 to 2030, coordinated by the Biomedical Research Foundation of the Academy of Athens.

Project on CORDIS →
Horizon Europe · MSCA-SE · 101130240

CHIRON

Cancer immunotherapy and signal transduction

How tumours evade the immune system, and how to make them sensitive to cell death again. e-NIOS contributes in silico modelling of non-canonical death receptor signalling.

Project website →
EPAnEK · T2EDK-01291

TheraSyn

Antisense therapy for Parkinson's disease

Next-generation antisense molecules for Parkinson's disease. e-NIOS analysed the study's RNA-seq data to help assess the lead molecule's mechanism of action and identify molecular biomarkers.

EPAnEK · T2EDK-03126

BIOFOS

Metagenomics for cultural heritage

Metagenomic analysis of the microbes on monument stone surfaces, including the Eupalinian Aqueduct on Samos, to guide nano-biomaterials that protect them.

Marie Skłodowska-Curie · Horizon 2020

DISCOVER

Death-receptor signalling and tumour-immune editing, across cell death, immunology, structural chemistry and computational biology.

Network website →
Academic and industry network

INSPIRED

IRE1 biology and drug discovery for cancer and neurodegenerative disease.

Network website →
Training network

TRAIN-ERS

Endoplasmic reticulum stress in cancer, neurodegeneration, metabolic and inflammatory disease.

Network website →
Erasmus+ · Sector Skills Alliances

BioS

Computational biology and bioinformatics curricula for medical doctors.

Network website →
EU innovation network

INNOCENT

Multifunctional nano-pharmaceuticals for breast cancer, with e-NIOS as the computational biology partner.

TheraSyn and BIOFOS are co-funded by Greece and the European Union through the Operational Program Competitiveness, Entrepreneurship and Innovation (EPAnEK 2014–2020), call RESEARCH – CREATE – INNOVATE. [EU and EPAnEK logos]